Abstract: Alisertib (MLN8237) is an investigational, orally bioavailable, selective small-molecule inhibitor of Aurora A kinase. Aurora A is frequently amplified and overexpressed in various malignancies, correlating with poor prognosis, genomic instability, and resistance to standard therapies. In the context of metastatic breast cancer, Aurora A drives the epithelial-mesenchymal transition (EMT), promotes a cancer stem cell-like phenotype, and induces endocrine resistance. Alisertib has demonstrated promising pharmacological activity by reversing EMT, restoring endocrine sensitivity, and inducing mitotic arrest and apoptosis in breast cancer cells. Clinical evaluations have shown encouraging single-agent efficacy, particularly in hormone receptor-positive (ER+) and HER2-negative breast cancer subgroups. To overcome dose-limiting hematological toxicities and enhance efficacy, current clinical strategies focus on combining alisertib with targeted agents, such as fulvestrant, paclitaxel, and immune checkpoint inhibitors. Furthermore, the alisertib scaffold is being utilized in novel proteolytic targeting chimeras (PROTACs) to achieve complete degradation of Aurora A, representing a significant future perspective in overcoming kinase inhibitor resistance.
1. Introduction
Aurora A kinase is a serine/threonine kinase that plays a critical role in orchestrating numerous activities of cells transiting through mitosis, including centrosome maturation, mitotic entry, and spindle formation [1][2]. The gene encoding Aurora A is commonly amplified and overexpressed in a diverse array of cancer types, including breast cancer, which correlates with worsened survival outcomes and drives oncogenesis by causing genomic instability [1]. Because of its pivotal role in tumor progression and therapy resistance, Aurora A has emerged as an attractive therapeutic target.
Alisertib (MLN8237) is a highly selective, orally administered small-molecule inhibitor of Aurora A kinase [1]. It has been extensively evaluated in preclinical models and clinical trials across multiple solid and hematological malignancies. In metastatic breast cancer, Aurora A overexpression is implicated in driving highly invasive phenotypes and mediating resistance to standard endocrine therapies [1][2]. Consequently, the clinical development strategy for alisertib in breast cancer focuses on its ability to reverse these aggressive phenotypes and synergize with existing therapeutic regimens.
2. Pharmacological Activity
Alisertib has demonstrated notable pharmacological activity both as a single agent and in combination therapies for breast cancer. In a phase 2 clinical study evaluating single-agent alisertib in advanced solid tumors, an objective response rate of 18% was observed among women with breast cancer [1]. The antitumor activity was particularly encouraging in the hormone receptor-positive (ER+) and HER2-negative subgroups, where patients achieved a median progression-free survival of 7.9 months [1].
Given its mechanism, alisertib is highly active when combined with other agents. In metastatic or locally recurrent breast cancer, it is being evaluated in combination with microtubule-perturbing agents like paclitaxel (NCT02187991) [1][4]. Furthermore, because Aurora A induces endocrine resistance, alisertib exhibits robust inhibitory activity against tamoxifen-resistant and aromatase inhibitor-resistant breast cancer cells. A phase 1/2 trial is currently investigating the combination of alisertib with the estrogen receptor antagonist fulvestrant in patients with endocrine-resistant, ER+ metastatic breast cancer (NCT02219789) [1][2]. Preclinical models also highlight synergistic antitumor effects when alisertib is combined with mTOR inhibitors (e.g., MLN0128), PAK1 inhibitors (FRAX1036), and PD-L1 antibodies, the latter of which helps eliminate myeloid-derived suppressor cell (MDSC)-mediated immunosuppression in the tumor microenvironment [2].
3. Molecular Mechanism of Action
Alisertib selectively binds to and inhibits the catalytic activity of Aurora A kinase. In cancer cells, this inhibition disrupts normal mitotic progression, leading to delayed mitotic entry, the formation of abnormal monopolar or multipolar spindles, and misaligned chromosomes. This results in an accumulation of cells with a tetraploid (4N) DNA content that ultimately undergo apoptosis, senescence, or mitotic slippage [1]. In ovarian and breast cancer models, alisertib has also been shown to induce G2/M phase arrest followed by mitochondrial-mediated apoptosis via the inhibition of the PI3K/AKT/mTOR and p38 MAPK pathways [4].
In the specific context of breast cancer, Aurora A drives the transition of ERα+ breast cancer cells from an epithelial to a highly invasive mesenchymal phenotype (EMT). This transition is characterized by reduced ERα expression, loss of the CD24 surface receptor, and HER-2/Neu overexpression [1]. Alisertib reverses this EMT, suppresses the self-renewal ability of cancer stem cells, restores a CD24+ epithelial phenotype, and inhibits the development of distant metastases [1]. Additionally, Aurora A phosphorylates the estrogen receptor (ERα) at Ser167/Ser305 and activates SMAD5 nuclear signaling, which down-regulates ERα expression and causes resistance to anti-hormonal therapies (like tamoxifen and aromatase inhibitors). By inhibiting Aurora A, alisertib prevents this phosphorylation, thereby restoring sensitivity to endocrine therapies [1][2].
4. Structure-Activity Relationship (SAR)
Alisertib is a benzazepine-containing small molecule that functions as an ATP-competitive inhibitor, selectively targeting the ATP-binding pocket of the Aurora A kinase active site [1][2]. It is highly selective, demonstrating >200-fold greater potency against Aurora A compared to the structurally related Aurora B kinase in cellular assays [1]. Upon binding to the catalytic domain, alisertib induces an allosteric conformational shift in the Aurora A protein. This structural change disrupts Aurora A's non-catalytic scaffolding functions, such as its protein-protein interaction with N-Myc, exposing N-Myc to FBXW7 E3 ubiquitin ligase-mediated proteasomal degradation [1].
The structural properties of alisertib have also been leveraged to design next-generation therapeutics. Bifunctional small molecules known as PROTACs (proteolysis-targeting chimeras) have been developed by linking the alisertib scaffold to an E3-ubiquitin CEREBLON-binding moiety (such as thalidomide or pomalidomide) via ethylene glycol linkers (e.g., compound JB170). These PROTACs maintain the binding affinity of alisertib but induce the rapid ubiquitination and proteasomal degradation of the entire Aurora A protein, effectively eliminating both its catalytic and non-catalytic functions [2].
5. Current Limitations
The clinical efficacy of alisertib is frequently limited by its toxicity profile. Because it acts as a cell cycle inhibitor in highly proliferative tissues, the most common dose-limiting toxicities (DLTs) include severe myelosuppression (grade 3-4 neutropenia, leukopenia, anemia, and thrombocytopenia), fatigue, stomatitis, and alopecia [1][6]. Additionally, due to its benzodiazepine-like chemical structure, alisertib can cause central nervous system side effects such as somnolence, mood alterations, and memory impairment [1].
While alisertib shows single-agent activity, it is often modest, and some phase 3 trials in other indications (such as peripheral T-cell lymphoma) were discontinued because they failed to meet primary endpoints of superior progression-free survival compared to standard-of-care [1][2]. Furthermore, combining alisertib with traditional chemotherapies (like taxanes) requires complex dose and schedule modifications to prevent overlapping toxicities, complicating its clinical administration [1].
6. Future Perspectives
To maximize the therapeutic index of alisertib in metastatic breast cancer, future clinical development is heavily focused on rational combination strategies. Combining alisertib with targeted therapies—such as endocrine agents (fulvestrant), mTOR inhibitors, or immune checkpoint inhibitors (PD-L1 antibodies)—is expected to yield synergistic antitumor activity with a more favorable risk/benefit profile and fewer overlapping toxicities than combinations with traditional chemotherapy [1][2].
The identification and validation of predictive biomarkers will be crucial for the success of alisertib. Selecting patient populations based on specific molecular features, such as ER+/HER2- status, MYC amplification, or high Aurora A expression, will enable a precision medicine approach, ensuring that the drug is given to those most likely to respond [1][2]. Finally, the evolution of alisertib-based PROTACs represents a highly promising future direction. By degrading the Aurora A kinase entirely rather than merely inhibiting its ATP-binding site, these degraders may overcome acquired resistance to ATP-competitive inhibitors and provide deeper, more sustained clinical responses [2].
